Samsara Therapeutics Competitors and Similar CompaniesClear all

Samsara Therapeutics's competitors and similar companies include Parexel International, Accellacare UK, Lionex and Medpace.

	Samsara Therapeutics Samsara Therapeutics is a biopharmaceutical company offering solutions for the treatment of age-related diseases.	Parexel International Parexel International (MA) is a clinical research organization.	Accellacare UK Accellacare UK (formerly known as MeDiNova Research) is a clinical research company that provides clinical trial services.	Lionex Lionex is a company that produces and supplies mycobacterial antigens and monoclonal antibodies for research.	Medpace Medpace is a clinical contract research organization (CRO).
Founding Date	Founding Date 2018	Founding Date 1982	Founding Date 1997	Founding Date N/A	Founding Date 1992
Type	Type Private	Type Private	Type Subsidiary	Type Private	Type Public
Tags	Tags Healthcare biotech clinical research pharma platform	Tags Healthcare biotech clinical research pharma	Tags Healthcare biotech clinical research pharma	Tags Healthcare biotech clinical research medical diagnostics pharma platform	Tags Healthcare biotech clinical research pharma
Locations	Locations Lewes, US HQ	Locations Newton, US HQ Olivos, AR Vicente López, AR Brisbane, AU Macquarie Park, AU Wavre, BE Sao Paulo, BR see more	Locations Coventry, GB HQ	Locations Braunschweig, DE HQ	Locations Cincinnati, US HQ Buenos Aires, AR South Yarra, AU Leuven, BE Leuven, BE Sao Paulo, BR Toronto, CA see more
Employees	Employees 195% decrease	Employees 20,806	Employees 2433% increase	Employees N/A	Employees 5,90013% increase
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) £9.4m (FY, 2021)	Revenue (est.) N/A	Revenue (est.) $2.5b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods £1.6m (FY, 2021)	Cost of goods N/A	Cost of goods $1.8b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit £7.8m (FY, 2021)	Gross profit N/A	Gross profit $760.6m (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income £742.9k (FY, 2021)	Net income N/A	Net income $451.1m (FY, 2025)
Operating ⚠
Backlog	Backlog N/A	Backlog $4b (FY, 2017)	Backlog N/A	Backlog N/A	Backlog $2.7b (Q3, 2023)
Countries	Countries N/A	Countries 52 (FY, 2017)	Countries 55 (Apr, 2023)	Countries N/A	Countries 40 (Q3, 2023)